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Abstract To evaluate the clinicopathological significance
of NET-1 in human skin squamous cell carcinoma (SSCC).
The expression of NET-1 and Ki67 protein was detected
using immunostaining from 60 SSCC cases, 50 SIN sam-
ples and ten normal skin tissues. The vectors expressing
NET-1, siRNA NET-1 and shRNA NET-1 were con-
structed, as well as negative controls (target-off). In
transfected A431 cells, the expression of NET-1 was
detected by qRT-PCR, Western blot and immunofluores-
cence staining; the proliferation and migration of cells was
evaluated by MTT, flow cytometry, wound healing and
transwell chamber assays. The stable cell lines transfected
with shRNANET-1 was inoculated in nude mice for in vivo
study. (1) The levels of NET-1 were significantly higher in
SSCC (96.67 %) and SIN III (93.75 %) than that in SIN I
and II (41.18 %), (P \ 0.05). NET-1 expression was sig-
nificantly enhanced in spindle-cell SSCC (75 %) versus
other histological types (P \ 0.05). (2) The expression of
NET-1 in A431 cells transfected with siRNANET-1 or
shRNANET-1 was significantly decreased; the prolifera-
tion and migration of these cells were obviously inhibited
as compared to controls (P \ 0.05). (3) The growth of
subcutaneous tumors was significantly inhibited associated
with reduction in the expression of NET-1 vs. the negative
control or untreated group (P \ 0.05). The overexpression
of NET-1 in tumor cells may be closely related to the
malignant phenotype of SSCC. NET-1 RNAi used in this
study can specifically and effectively downregulate NET-1
gene expression; thus SSCC proliferation, invasion and
tumor growth were attenuated. NET-1 might be one of the
potential targets for SSCC therapy.
Keywords Skin squamous cell carcinoma (SSCC) 
NET-1 (TSPAN1, TSPAN1/C4–8)  RNA
interference (RNAi)
Introduction
Skin squamous cell carcinoma (SSCC) is among the top
three common skin cancers, ranking behind basal cell
carcinoma (BCC) and ahead of melanoma. SSCC is a
significant public health problem despite their low mor-
tality rate [23]. Most cases arise from the sun-exposed skin
of elderly people, because the solar radiation causes DNA
alterations and mutations in DNA replication. A number of
potentially useful molecular markers or tests have been
proposed, these include some novel genes and proteins
closely related to the carcinogenesis, development and
prognosis [11, 16, 22], which may be of great significance
for early diagnosis and treatment of SSCC.
NET-1 (or TSPAN1, TSPAN1/C4-8, Gene ID: 10103)
and NET2-7 are called NET-X, which are members of
seven transmembrane four superfamily (TM4SF) found by
Serru in 2000 in EST database [25, 27] TM4SF is a group
of proteins containing four hydrophobic transmembrane
domains forming two extracellular loop structures with
different size. Its N-terminal and C-terminal were located
in the cytoplasm. Currently, TM4SF members have
increased to 25, although their amino acid sequence share a
high homology, there are significant differences between
different tissues and cells, particularly the recently reported
J. zhang  J. Wang  Y. Xu
Dermatology Department, Affiliated Hospital of Nantong
University, Nantong 226001, People’s Republic of China
J. Wang  L. Chen (&)  G. Wang  J. Qin  X. Li
Department of Pathology, School of Medicine, Nantong
University, Nantong 226001, People’s Republic of China
e-mail: bl1@ntu.edu.cn
123
Arch Dermatol Res (2014) 306:385–397
DOI 10.1007/s00403-013-1423-9
TM4SF molecules, such as CD9, CD63, CD82, CO-029,
PETA-3/SFA-1, SAS, etc., which have been identified as
tumor-associated proteins[14, 18, 25, 27]. NET-1 gene is
located at chromosome 1 p34.1, and its mRNA is 1,297 bp
long encoding a protein with 241 amino acids. In prior
study from this laboratory, NET-1, as a new member of
TM4SF plays an important role in cell signal transduction
[8, 9, 25, 27], and is closely correlated with proliferation,
invasion and poor prognosis of cancers [3, 5, 7–10]. NET-1
has been identified through the serial analysis of gene
expression (SAGE) database as overexpressed in breast and
gastric adenocarcinoma cells [1, 15]. The NET1 gene has a
key role in organization of the actin cytoskeleton and thus
in the ability of cancer cells to migrate and invade. We
found that NET-1 was frequently expressed at a higher
level in hepatocellular carcinoma tissue than in peritumoral
tissue [6]. Thus, NET-1 may be a suitable target for gene
therapy. Thus far, to our knowledge, there have not been
any reports investigating the delivery of NET-1 siRNA into
human skin squamous cells.
RNA interference (RNAi) has already become an
effective way to identify gene function. The mechanism for
RNAi function to silence a target gene is to form a
silencing complex (RNA-induced silencing complex,
RISC) with the target gene, thereafter degrades its mRNA,
resulting in reduction of corresponding protein translation
[12, 19].
In this study, we examined the expression of NET-1
protein in human SSCC and skin intra neoplasia (SIN)
tissues by immunostaining to assess its clinical and path-
ological significance. Meanwhile, Ki67 was also detected
in these SSCC specimens because it is an important cell
proliferation marker which was overexpressed in many
cancers and closely correlated with malignant biological
behavior and prognosis of many cancers [10, 17]. In
addition, we designed shRNA and siRNAs against NET-1,
and constructed them into vectors prior to transfected into
an epidermoid carcinoma cell line (A431 cells) to identify
the effects of NET-1 gene on A431 cells and the growth of
transfected A431 cell xenograft in nude mice. Though
investigating the expression and function of NET-1 gene,
this study will provide a potential target to treat skin
carcinoma.
Materials and methods
Cases and immunohistochemical staining
A total of 60 SSCC cases, 50 cases of SIN (I–III) and ten
specimens from the marginal normal skin of breast cancer
as normal controls were provided by department of der-
matology, Nantong University Affiliated Hospital, China.
The study was approved by the local committee of medical
ethics, and written prior informed consent and approval
were signed by the participants.
All surgically resected samples were routinely fixed in
40 g/L formaldehyde solution and embedded in paraffin.
Immunohistochemical staining was performed to detect the
NET-1 and Ki67 expressions in the sections using Dako
Elivision TM Plus Two-step System (PV-6000 kit, Zymed,
Co. USA). In brief, 4 lm sections were dewaxed in xylene
and rinsed in alcohol and graded alcohol/water mixtures.
The sections were treated in sodium citrate buffer (10 mM
sodium-citrate monohydrate, pH 6.0) in a pressure cooker
for antigen retrieval. Subsequently, they were treated again
with 0.3 % hydrogen peroxide in absolute methanol to
inhibit endogenous peroxidase activity. And then the sec-
tions were incubated with diluted normal calf serum to
prevent from non-specific staining prior to interaction, with
rabbit anti-human polyclonal antibodies against NET-1
(antibody was prepared with the cooperation of San Fran-
cisco gene biotechnology Co. USA, dilution 1:200) [3, 5, 7,
10], or mouse anti-human monoclonal antibody Ki67
(Lot:41081001, ZYMED CO,USA, dilution 1:100), over-
night at 4 C. Then, slides were washed with 0.05 %
Tween 20 in TBS (pH7.4). Detection was achieved with
the DAKO envision?/HRP system (Dakocytomation). The
color was developed by 15 min incubation with peroxi-
dase-3,30-diaminobenzidine (DAB) solution (DAB kit IL1-
9032). Finally, sections were weakly counter stained with
Mayer’s hematoxylin. Negative controls were made by
omitting the primary antibodies. The positive controls were
the hepatocellular carcinoma that was proved to express
NET-1 and Ki67. Simultaneously, epithelial membrane
antigen (EMP) (Lot:41081001, ZYMED CO, USA, dilu-
tion 1:100) and higher molecular weight cytokeratin (CK)
(Lot:41081001, ZYMED CO,USA, dilution 1:100) were
detected to determine tumor original.
All sections were blindly analyzed by two experienced
pathologists. Based on the estimated percentages of positive
parenchyma cells and/or the immunostaining intensity,
which was determined by comparing the immunoreactivity
of the positive controls that were included in each experi-
ment, staining results were divided into four categories: (-)
positive parenchyma cells were less than 5 % and/or with
weakly stained, (?) positive parenchyma cells were ranged
from 5 to\50 % and/or with weakly stained, (??) positive
parenchyma cells were ranged from 50 to \75 % and/or
with moderately stained, and (???) positive parenchyma
cells were more than 75 % and/or with strongly stained
[3, 5, 7, 10].
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Plasmid construction
pSilencer 4.1-CMV neo-GFP vector with a neo resistance
gene, 4.944 kp and pU6H1-GFP vector (the vector length in
the U6 and H1 is 5.1 kp, and there is no extra cloning
sequence site in the siRNA fragment between the promoter
starting sequence AAAAA and ending sequence TTTTT)
were purchased from Ambion Inc. and Qiagen Inc., respec-
tively. According to the NET-1 sequences in the gene bank
(library number AF065388), Qiagen siRNA designing soft-
ware and network computing tools (http://jura.wi.mit. Edu/
bioc/siRNA) [2, 13, 20, 21, 26] were used to design siRNA
sequence (23 bp) targeting NET-1 and shRNA sequence
(55 bp) at 50–100 nt downstream of the mRNA starting
codon AUG. The sequence alignment (BLAST) was carried
out to ensure specificity and to determine no homology with
other human genome. Then, the corresponding DNA
sequence was further synthesized by enzyme digestion,
ligation, transformation, thus, specific plasmids against
siRNA NET-1 and shRNANET-1 were constructed. The
random sequences (off-target) in shRNA(shRNA targeting
off-T)and siRNA (siRNA targeting off-T) were used as the
non-specific negative controls. The sequence and length in
recombinant plasmids were shown in Table 1.
Cell culture and transfection
A431 cell line (from an epidermoid carcinoma of a 85 old
female patient) was a gift from Dr. Gao Tianwen in the
military Institute of Dermatology of West Beijing Hospital,
Fourth Military Medical University in Xi’an, China. The
A431 cells were maintained in DMEM plus 10 % fetal
bovine serum and 1 % penicillin/streptomycin (Life
Technologies) in a 37 C, 5 % CO2 environment. The cells
were transfected with the above plasmids using Lipofect-
amineTM2000 transfection reagent (USA Invitrogen Corpo-
ration), according to the manufacturer’s instructions. The
cells were analyzed at 48 or 72 h after transfection. Cells
were used for the below experiments after they were pas-
saged 4–10 times.
Real-time quantitative polymerase chain reaction
(qRT-PCR)
One-hundred twenty-five lg of cDNA per reaction was
used for qRT-PCR using SYBR Green reagents and ana-
lyzed on ABI Prism 7700 Sequence Detector (Applied
Biosystems, Foster City, CA, USA). Upstream and down-
stream primers of NET-1 0.5 ll (10 pmol/ll) were
designed (NET-1-S: 50-GTGGCTTCACCAACTATACG-
30, NET-1-AS: 50-GACTGCATTAGTTCGGATGT-30).All
reactions were performed in a 25 ll volume with 150 nM
primers, 0.25 units of Amp Erase Uracil-N-glycosylase and
19 SYBR Green PCR Master Mix (Applied Biosystems).
The thermal cycling profile consisted of a 95 C denatur-
ation step for 10 min, then 40 cycles at 95 C for 20 s,
62 C for 30 s and 72 C, 30 s annealing extension. All
samples were run in duplicate. GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) was used as reference gene.
(GAPDH-S: 50-GAAGGTGAAGGTCGGAGTC-30, GAP-
DH-AS: 50-GAAGATGGTGATGGGATTTC-30). Each
was 1.0 ll (6 pmol/ll) and compared to a standard curve
created using Universal Human Reference RNA (Strata-
gene, Cedar Creek, TX, USA). To exclude non-specific
amplification and primer–dimer formation, a dissociation
curve analysis was performed.
Western blot
Harvested cells were washed once with PBS, and lysed in
Phosphosafe (Novagen, Madison, WI). Protein concentra-
tions were determined by Bradford analysis using Coo-
massie Plus Protein Assay Reagent (Pierce, Rockford, IL)
and equivalent concentration of each sample was mixed
with 29 SDS sample buffer [0.1 mol/L Tris–HCl (pH 6.8),
4 % SDS, 20 % glycerol, 0.1 % bromophenol blue, 5 %
b- mercaptoethanol], boiling for 5 min, and 10 ll was
loaded for electrophoresis. After running in sodium dode-
cyl sulfate–polyacrylamide gels (5 % spacer gel, 12 %
separating gel), semi-dry transfer apparatus (BIO-RAD,
Inc.) was used to transfer proteins on the gels onto PVDF
Table 1 Sequences of shRNA and siRNA expressing insertions





shRNA off-T-S 50-GATCCGGAGTACCCTGATGAGATCTTCAAGAGAGATCTCATCAGGGTACTCCTGA-30 55
shRNA off-T-AS 30-GCCTCATGGGACTACTCTAGAAGTTCTCTCTAGAGTAGTCCCATGAGGACTTCGA-50
siRNA off-T-S 50-GAGTGATTGGAGGTTGGGGAC-30 21
siRNA off-T-AS 30-CTCACTAACCTCCAACCCCTG-50
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membranes. After been blocked with 5 % skim milk, the
membranes were incubated with rabbit anti-human NET-1
polyclonal antibody (1:800) overnight at 4 C.The horse-
radish peroxidase labeled goat anti-rabbit IgG antibody
(1:1,000) was used to probe primary antibody and interact
with ECL (Amersham Bioscience). The housekeeping gene
product, b-actin, was used to normalize sample proteins.
Immunofluorescence staining
The transfected cells sticked on the slides were fixed with
4 % paraformaldehyde for 2 h, and then 10 % normal goat
serum was added at 37 C for 1 h, followed by the incu-
bation of rabbit anti-human NET-1 polyclonal antibody
(1:200) and mouse anti-human monoclonal antibody ki67
(1:200) at 4 C overnight. PBS was used as a negative
control. After PBS wash three times, FITC-goat-anti-rabbit
IgG (1:100) and TRITC-goat-anti-mouse IgG (1:100) were,
respectively, incubated in dark at 4 C overnight. Hochest
33258 was used to stain nuclei for 10 min (final concen-
tration of 50 g/ml), mounted by buffer glycerol and pho-
tographed under fluorescent microscope. For FITC, the
excitation wavelength is 488 nm; for TRITC, the excitation
wavelength is 550 nm; for Hochest, the excitation wave-
length is 353.6 nm. The mean ratio was obtained by
counting positive cells in at least five random fields per
field (magnification 40 9 10).
MTT assay
At 24 h after transfection, A431 cells in logarithmic growth
phase were treated by 0.25 % trypsin and collected,
DMEM medium with 10 % newborn calf serum was used
to make single cell suspension, and seeded in a 96-well
plate by 1 9 104 cells/well, then 150 ll medium was
added to each well. The cells were cultured in an incubator
at 37 C containing 5 % CO2. The detection was taken at 0,
24, 48 and 72 h. Each well was added with 20 ll MTT
(5 g/L, Biobasic Company) solution, cultured for another
4 h, then the medium was discarded, 150 ll DMSO was
added to each well for 10 min at 37 C, gently vibrating to
dissolve crystal. The absorbance of each well was mea-
sured by microplate reader (wavelength 570 nm).
Flow cytometry (FCM)
At 48 h after transfection, about 106 cells suspensions were
collected and centrifuged at 1,000 rpm for 5 min. The
pellets were washed twice with ice-cold 0.01 mol/L PBS
and fixed in pre-cooling 70 % ethanol at 4 C overnight.
After washing twice with PBS, cells were incubated in PBS
with 5 mg/mL propidium iodide (PI) staining of nuclei and
50 mg/mL RNase A in dark for 30 min at 4 C. The red
fluorescence of DNA-bound PI in cells was measured at
488 nmol/L with a FACS Calibur flow cytometer (Becton–
Dickinson, USA). The results were analyzed using the
CellQuest software. The percentages of cells in each cycle
were measured for each sample. The proliferation index
(PI) of each group was calculated, PI = (S ? G2/M)/(G0/
G1 ? S ? G2/M).
Cell migration assay by ‘‘wound’’ lane
The cells were seeded into 96-well plates (1.5 9 105/well)
the day before transfection allowing their growth up to
100 % confluence (about 6 h after transfection). A straight
lane as made on the cell layer using pipet tip to form a
‘‘wound’’ lane. After 24, 48 and 72 h, the relative distances
of cell migration from the edges were measured by image
software (Image-ProPlus, version 4.5.1, USA) [4].
Cell migration assay by transwell chambers
Cells were harvested 24 h after transfection; cells were
then seeded into 24 transwell inserts (the upper chamber)
filled with DMEM without serum. The lower chamber was
supplemented with 500 ll DMEM medium with 10 % FCS
serum. The upper and lower chambers were separated by
an 8 Am pore polycarbonate membrane (Costar, Corning,
NY) which was coated with 50 ll of 0.5 mg/ml Matrigel.
The cells on the upper surface of the inserts were carefully
removed at 36 h after transfection with a cotton swab.
Migration cells on the lower surface of the inserts were
counted in five random high-powered fields (HPF,
40 9 10) per membrane, and the average number of
migrating cells per HPF was calculated.
Nude mice SSCC xenograft models
To guarantee the cells that were used to develop xenografts
in nude mice were stably transfected with shRNA, colony
formation assays were performed to select single-cell colo-
nies at 2–3 weeks after growth in soft agar. And then the
selected single-cell clones were expanded in the medium
containing G418. A431 cells with off-T shRNA control were
also selected by G418. The subcutaneous xenografts in nude
mice were developed by inoculation of the above cells into
animals. Six to eight-week-old specific pathogen-free athy-
mic nude mice (BALB/c Nude, female) were fed with ster-
ilized food, water, and housed in a barrier facility with 12 h
light and dark cycles. All procedures were conducted at the
animal experiment center of Nantong University, according
to guidelines laid out by the Institutional Animal Care and
Use Committee. The treated or untreated cells (2 9 106) in
0.2 ml PBS were injected subcutaneously into both sides of
the mice nape (n = 6 for each group, total 18). The tumor
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masses were measured every 3 days with a caliper, and
tumor volume was calculated by the formula: volume = (1/
6) pab2 (where a and b represent two perpendicular tumor
diameters) [21]. Regression in subcutaneous tumor growth
was followed up for 3 weeks. After mice were euthanized,
subcutaneous tumors were removed and fixed in buffered
formaldehyde (4 % wt/vol in PBS). 4-lm paraffin sections
were stained in hematoxylin-eosin (H&E) using standard
histological techniques.
Quantification of necrotic area: In sections, the mean
size of tumor necrotic area was determined in five random
fields under microscope.
Statistical analysis
Paired data were analyzed using Student’s t test; rank
correlation data were analyzed using the Spearman test;
relationships between NET-1 expression and Ki67
expression, clinicopathological parameters were analyzed
using the v2 test. For all statistical analyses, a difference
with P \ 0.05 was considered significant. In vitro, all tests
were transfected into three parallel wells each repeated
three times. The untransfected group was taken as a control
for comparison. The relative distance of cell migration and
migrating cells per transwell chamber membrane, the vol-
ume and weight of nude mice xenografts etc., were pre-
sented as mean ± SD, respectively. SPSS for Windows




Of the 60 SSCC cases, 66.67 % of lesions (40 cases)
occurred on forehead, face, ears, scalp neck and dorsum of
the hands and vermilion part probably due to sunlight
exposure; 33.33 % (20 cases) occurred on the soles of the
feet and back. Among them, 43 cases were males and 17
females with a median age of 66.7 (range 34–92). None of
the patients received chemotherapy or radiotherapy before
diagnosis. The average size of the tumor was 2.4 cm (range
1.2–4.6 cm). The clinicopathological features were deter-
mined according to WHO histological classification of
keratinocytic skin tumors and TNM stage of skin carci-
nomas [6, 15]. SSCC cases were divided into general SSCC
(31 cases, 51.67 %), acantholytic SSCC (10 cases,
16.67 %), spindle-cell SSCC (8 cases, 13.33 %), verrucous
SSCC (9 cases, 15 %), and other types (2 cases, 3.33 %)
Fig. 1 The expressions of NET-1 in SIN and SSCC. Paraffin section
of SSCC was stained with anti-NET-1 polyclonal antibody immuno-
cytochemistry methods. NET-1 located in the cytoplasm, yellow
granulation. NET-1 expressed negatively in normal skin (a), evenly in
the basal layer and spinous layer in SIN II (b), in the full epithelial
layer in SIN III(c), strongly in SSCC (d), especially in lower
differentiated (e) and metastatic carcinoma emboli of blood vessel (f).
Magnification 9200
Table 2 Comparison of NET-1 expressions between SSCC and SIN
I–III
Cases NET-1
- (%) ? (%) ?? (%) ??? (%)
SINI-II 34 20 (58.82) 10 (29.41) 4 (11.76) 0 (0.00)
SINIII 16 1 (6.25) 2 (12.50) 6 (37.5) 7 (43.75)
SSCC 60 2 (3.57) 8 (13.33) 21 (35.0) 29 (48.33)
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which included pseudovascular SSCC (1 case) and ade-
nosquamous carcinoma (1 case). SIN were divided into I–
III, SIN I–II (total 34 cases) attributed to low grade with
mild or moderate atypical hyperplasia; SIN III (16 cases)
belonged to high grade with atypical keratinocytes
involving over 2/3 full-thickness of epidermis and carci-
noma in situ. Infiltrating tumor status (T): the size of T1
tumor was 2 cm or less in maximum dimension (stage I 21
cases, 35 %); T2 tumor size was 2–5 cm (27 cases,
45.0 %), and T3 tumor size was over 5 cm in greatest
dimension (8 cases, 13.33 %), both T2 and T3 is attributed
to the stage II (35 cases, 58.33 %), T4 tumor infiltrated
deep extradermal area (1 case, 1.67 %). Tumor with either
T4 or regional lymph node metastasis (3 cases, 5.0 %)
belonged to stage III (4 cases, 6.67 %). None of the cases
was stage IV (tumor with distant metastasis). Grossly,
28.33 % (17 cases) were shallow ulcer, 53.33 % (32 cases)
were plaques or nodules, and 18.33 % (11 cases) were
cauliflower-like appearance. According to the states s of
keratocyte differentiation and dysplasia appearances, the
SSCC were divided into well (19 cases, 31.67 %), mod-
erately (29 cases, 48.33 %) and poorly differentiation (12
cases, 20 %). The thickness of tumor was evaluated
according to the depth of tumor growth and invasion:
\2 mm 28.33 % (17 cases), 2–5 mm 60 % (36 cases),
[5 mm 11.67 % (7 cases).
Table 3 Significant correlation between NET-1 expression and clinical pathological factors in SSCC
Cases NET-1
- (%) ? (%) ?? (%) ??? (%)
Ki67 expression*
? 12 1 (8.33) 5 (41.67) 3 (25.00) 3 (25.00)
?? 14 1 (7.14) 2 (14.29) 5 (35.71) 6 (42.86)
??? 34 0 (0.00) 1 (2.94) 13 (38.24) 20 (58.82)
Thickness*
\2 mm 17 1 (5.88) 5 (29.41) 8 (47.06) 3 (17.65)
2–5 mm 36 1 (2.78) 3 (8.33) 12 (33.33) 20 (55.56)
[5 mm 7 0 (0.00) 0 (0.00) 1 (14.29) 6 (85.71)
TNM stages
I 21 1 (4.76) 4 (19.05) 10 (47.62) 6 (28.57)
II 35 1 (5.25) 4 (11.42) 10 (28.57) 20 (57.14)
III 4 0 (0.00) 0 (0.00) 1(0.25) 3 (0.75)
Pathologic type*
General 31 1 (3.22) 3 (9.68) 10 (32.25) 17 (54.84)
Spinous-release 10 0 (0.00) 2 (20.0) 5 (50.0) 3 (30.00)
Spindle-cell 8 0 (0.00) 0 (0.00) 2 (25.00) 6 (75.00)
Verrucous 9 1 (11.11) 4 (44.44) 2 (22.22) 2 (22.22)
Others 2 0 (0.00) 0 (0.00) 1 (50.0) 1 (50.0)
Gross appearance
Shallow ulcer 17 1 (5.88) 3 (17.65) 6 (35.29) 7 (41.12)
Plaques or nodules 32 0 (0.00) 4 (12.5) 12 (37.5) 16 (50.00)
Cauliflower like 11 1 (9.09) 1 (9.09) 3 (27.27) 6 (54.55)
Differentiation
Well 19 2 (10.53) 5 (26.32) 8 (42.11) 4 (21.05)
Moderately 29 0 (0.00) 2 (7.00) 11 (37.93) 16 (55.17)
Poorly 12 0 (0.00) 1 (8.33) 2 (16.67) 9 (75.00)
Sites
Sunlight exposure 40 2 (5.00) 7 (17.5) 14 (35.00) 17 (42.5)
Non exposure 20 0 (0.00) 1 (5.00) 7 (35.00) 12 (60.0)
Sex
Male 47 2 (4.25) 5 (10.64) 17 (36.17) 23 (48.94)
Female 13 0 (0.00) 3 (23.08) 4 (30.76) 6 (46.15)
* The difference was significant in groups compared (P \ 0.05)
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Immunohistochemical results showed: NET-1 and CK
were positively located in cytoplasm, EMP positively loca-
ted in cytomembrane and Ki67 was positively located in the
nucleus. All cases from human samples were confirmed from
keratinocyte origin by EMA and CK immunostaining. All
positive controls expressed NET-1 and Ki67. In contrast, no
positive staining was found in negative groups.
NET-1 expression in SIN and SSCC
The basal layer in normal skin did not or weakly express
NET-1. In contrast, NET-1 was expressed in some SIN
cases. In SIN I–II cases, the cells expressing NET-1dis-
tributed evenly in the basal layer and spinous layer with
weak staining, and in the 2/3 upper epidermis with normal
squamous differentiation. The positive rates for NET-1 in
SIN I–II were 44.22 % (15/34). In SIN III, the cells with
NET-1 were located in the full epithelial layer, and the
positive rate was 93.75 % (15/16). In 96.67 % (58/60)
SSCC cases, NET-1 was stained intensively with polar
disorder, and the expression was enhanced in cells infil-
trating stroma and in metastatic emboli in blood vessels
(Fig. 1). Comparison of NET-1 expressions between SSCC
and SIN was shown in Table 2.
Chi-square test (Table 2) showed that there was a sig-
nificant difference in intensity of NET-1 staining among
SSCC, SIN III and SIN I–II (v2 = 58.22, P \ 0.01). NET-
1 expression was gradually enhanced from SIN I–II to SIN
III and SSCC. Spearman grade analysis suggested an
obvious positive correlation among them (r = 0.6077,
P = 0.0000). In intensity of NET-1 staining, there was a
significant difference between SIN I–II and SIN III
(v2 = 26.9345, P \ 0.01), but no significant difference
between SSCC and SIN III (P [ 0.05).
Correlation between NET-1 protein expression
and the clinicopathological parameters of SSCC
The correlation of NET-1 expression with the clinico-
pathological parameters in SSCC was analyzed (Table 3).
There was a correlation in NET-1 expression between Ki67
expression (v2 = 15.2906, r = 0.3430, every P \ 0.05)
(Fig. 2), tumor thickness (v2 = 12.8197, r = 0.3220, every
P \ 0.05), or cancer differentiation (v2 = 14.3131,
r = 0.0.3542, every P \ 0.05). The expression of NET-1
in spindle-cell carcinoma appeared to be more obvious than
that in other types, but there was no significant difference
between NET-1 expression and SSCC TNM stages, lesion
sites, sunlight exposure, gender and age (P [ 0.05).
Inhibitory effect of RNAi on NET-1 expression
in A431 cells
qRT-PCR and Western blotting showed that NET-1 mRNA
and protein expression were significantly inhibited in A431
cells transfected with siRNANET-1 or shRNANET-1
(Fig. 3).
Impact of RNAi on A431 cell proliferation
The transfected A431 cells revealed that both siRNANET-
1 and shRNANET-1 were able to significantly attenuate
cellular proliferation as compared to negative control or
untreated cells (P \ 0.05). Furthermore the growth curve
Fig. 2 The expressions of NET-1 and Ki67 in SSCC. Paraffin section
of SSCC was stained with anti-NET-1 polyclonal antibody (a) and
Ki67 monoclonal antibody (b) immunocytochemistry methods. NET-
1 located in the cytoplasm, Ki67 located in the nuclear; a1, b1 well
differentiated; a2, b2 middle differentiated and a3, b3 lower
differentiated; magnification 9200
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showed that the inhibiting efficiency in A431 cells trans-
fected with shRNANET-1 was longer than that in siR-
NANET-1 after 72 h (P \ 0.05) (Fig. 4). The proliferation
index (PI) and cell proportion in every cell cyclic phase
were obtained by FCM (Table 4). From Table 4, the cells
arresting in G0/G1 or G2/M phase were increased, and PI
were decreased in cells transfected with siRNANET-1 or
shRNANET-1 (P \ 0.05 vs. the control). In addition,
immunofluorescent staining revealed immunoreactivity of
NET-1 in cytoplasm,while Ki67 was in nuclei. Two
markers were positively correlated in cell (Fig. 5). The
expressions of NET-1 and Ki67 were reduced in the cells
treated with siRNANET-1 or shRNANET-1 (P \ 0.05),
which indicated that NET-1 gene was involved in cell
proliferation.
Inhibitory effect of RNAi on migration of A431 cells
Wound healing assay and Transwell small chamber test
showed that the migration of the cells with siRNANET-1
or shRNANET-1 was significantly affected at 24 h after
transfection (P \ 0.05) (Fig. 6). However, there was no
significant difference in NET-1 expression and migration
between the negative controls and untreated cells, or
between siRNA NET-1 and shRNA NET-1 (P [ 0.05). But
the above growth curve shown the inhibiting efficiency in
Fig. 3 shRNA targeting NET-1 downregulating the expression of
NET-1 mRNA and NET-1 protein in A431 cells. a RT-PCR analysis
for NET-1 expression. GAPDH was used as a loading control. Mean
densitometric values ± SEM were calculated and plotted as a
histogram. b Western blot analysis of the expression of NET-1
protein. a The band of NET-1 (38 kD) and b-actin (41 kD); b The
optical density of NET-1 to b-actin. The untreated group was taken as
1. Asterisk statistically different compared to negative control
(P \ 0.05, respectively); hash symbol statistically different compared
to untreated cells (P \ 0.05, respectively). Experiments were
repeated at least three times
Fig. 4 shRNA targeting NET-1 inhibited A431 cells proliferation
Cell proliferation was measured at different time-points as described
in Materials and methods. The histogram of growth curve showed a
statistical difference in A431 cells transfected with shRNANET-1
from 48 to 96 h and transfected with siRNANET-1 between 48 and
72 h. Experiments were repeated at least three times. (*P \ 0.01
indicates significant vs. negative control or untreated cells, #P \ 0.05
indicates significant vs. A431 cells transfected siRNANET-1)
Table 4 Cell cycle percentage and proliferation index (PI) of each
group 48 h after transfection
A431 cells transfected with Cell cycle
G0/G1
(%)
G2/M (%) S (%) PI
shRNA NET-1* 70.57 6.78 22.65 29.43
siRNA NET-1* 68.63 10.24 21.13 31.37
shRNA off-T 52.02 14.95 33.03 47.98
siRNA off-T 51.76 15.69 32.55 48.24
Untreated 51.17 11.56 37.27 48.83
* Respectively compared with the control group and untransfected
group, the difference was significant in cell cycle and PI (P \ 0.05)
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shRNA was stronger than that in siRNA, so shRNANET-1
was selected to use in vivo.
Suppression of tumor growth in vivo by NET-1 shRNA
The volume and weight of tumor xenografts in nude mice
were markedly decreased over 50 % of the negative control
or untreated cell group at 20 days after inoculation with
NET-1 shRNA cells (0.12 ± 0.02 g/192.50 ± 0.40 mm3,
vs. 0.26 ± 0.42 g/295.19 ± 5.44 mm3 or 0.25 ± 0.12
g/276.00 ± 11.04 mm3) (P \ 0.05) (Table 5). Histologi-
cally, cancer nests with cellular apoptosis were much
obvious in shRNANET-1 tumors; whereas the larger can-
cer nest with foci necrosis was prominent in untreated
group (Fig. 7). As expected, qRT-PCR and immunohisto-
chemical assays revealed that the levels of NET-1 mRNA
and protein in shRNA NET-1 xenograft tumors were lower
than those in the untreated cells and the negative control
Fig. 5 Immunofluorescence staining NET-1 and Ki67 expressed in
A431 cells. Nuclei stained by Hoechst in blue (a), homogeneously
Ki67 stained by TRITC in red located in the nuclei (b), NET-1
stained by FITC in green located in the cytoplasm (c) in A431 cell
lines. Merged figure (d)
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Fig. 6 shRNA targeting NET-1
inhibiting the migration of A431
cells. a Wound healing assay of
the cells migration. a Migration
cells were measured and
photographed under a light
microscope at 24, 48 and 72 h
as described in ‘‘Materials and
methods’’ (9100). b Average
values of three separate
experiments are shown and bars
represent the mean ± SE.
b Transwell small chamber test
of cells invasion. a Invasion
cells in the down room of
transwell small chamber were
counted under a light
microscope at 36 h as described
in ‘‘Materials and methods’’
(9200). b Quantification of
invading cells. The bars
represent the mean ± SE of
three different experiments.
Asterisk statistically different
compared to negative control
(P \ 0.05, respectively); hash
symbol statistically different
compared to untreated cells
(P \ 0.05, respectively)
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(P \ 0.05), which was consistent with those of human
SSCC or in vitro A431 cell study.
Discussion
In this study, the expression of NET-1 protein was
detected in 60 human SSCC cases, 50 SIN cases and 10
normal human skin samples to identify the correlation
between NET-1 and different skin pathological types. In
normal epithelial and SIN I–II cells, NET-1 was not or
weakly stained predominantly in the basal and spinous
layers. In SIN III and SSCC, NET-1 expressed strongly in
full epithelial layer with polar disorder. The positive ratio
of NET-1 expression was significantly higher in SSCC
and SIN III than that in SIN I–II. Spearman grade cor-
relation analysis demonstrated an obvious positive corre-
lation from SIN I–II to SIN III and SSCC. No significant
difference between SSCC and SIN III, suggested that
SIN III belongs to tumor hyperplasia. And the process
of SSCC closely related to upregulated NET-1 expres-
sion. Our results strongly supported that the NET-1
Table 5 The volume and weight of nude mice xenograft tumors x  Sð Þ (n = 6)
Group Volume (mm3) Weight (g) Necrotic area (%)
shRNA NET-1* 192.50 ± 0.40 0.12 ± 0.02 12.5 ± 16
shRNAoff-T 295.19 ± 5.44 0.26 ± 0.42 25.9 ± 31
Untreated 276.00 ± 11.04 0.25 ± 0.12 28.8 ± 09
* Respectively compared with the control group and untransfected group, the difference was significant in tumor volume, weight and necrotic
area (P \ 0.05)
Fig. 7 The model and histological manifest of mice xenografts
tumor. In vivo, the growth of 20 days after mice xenografts tumor, the
tumor was smaller in shRNANET-1 treated tumors than that in
untreated cells and the negative control (the first rank). Histologically,
cellular apoptosis (white arrow) prominently occurred in shRNA
NET-1 treated tumors, whereas the large area necrosis (black arrow)
was prominent in untreated group (the second rank, HE staining,
magnification 9100). The expression of NET-1 protein in shRNA-
NET-1 treated tumors was lower than that in untreated cells and the
negative control (the third rank, immunohistochemistry stain, mag-
nification 9200)
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overexpression might be an early molecular event in
SSCC malignant transformation. In this study, we noticed
that NET-1 overexpression implied a cellular response to
malignant transformation. Because spindle-cell SSCC is
characterized by rapid growth, the poorer differentiation
with more mitostic figures, in this study shows that
spindle-cell SSCC showed higher expression of NET-1,
which suggests that NET-1 may be a marker for cell
differentiation phenotype. In addition, NET-1 expression
was obviously correlated with tumor infiltrating; it sug-
gests the accumulation of NET-1in cancer cells closely
related to the malignant progress of SSCC. These results
are similar to Wollscheid V’s investigation [24]. They
found that NET-1 gene was expressed in CIN III, cervical
squamous cell carcinoma, all undifferentiated cervical
carcinoma and adenocarcinoma, indicating that NET-1
gene may be a marker for cervical cancer.
NET-1, the same as TM4SF accumulated in clonal cell
surface of SSCC, may transduct signal of cell proliferation,
synergistically promotes SSCC invasion and metastasis
[18]. Though Co-expression of Ki67 with NET-1 in tumors
was performed to evaluate cancer cell proliferation, the
results showed that NET-1 might function with Ki67 to
increase tumor cell proliferation. Similarly, several reports
have correlated the invasive and metastatic potential of
cancers with activity and expression of NET-1 in different
cancers [5, 7–9, 14, 18].
We used RNAi technique to downregulate NET-1 in
A431 cell line. As shown by Western blotting and qRT-
PCR, transient transfection with siRNA or shRNA against
NET-1 significantly decreased endogenous NET-1
expression and activity, which affected cell cycles, leading
to cell arrest in G0/G1 or G2/M phase. In addition, the
expression of NET-1 in cytoplasm or membrane of A431
cells indicated that NET-1 molecule might receive extra-
cellular signals through transmembrane to function in
cytoplasm. The impairment of A431 cell migration capa-
bility might be attributed to the downregulation of NET-1.
Furthermore, the results in vivo suggested that shRNA
NET-1 could significantly downregulate the expression of
NET-1 in nude mice xenografts models, leading to stunt
the tumor growth and downregulate malignant phenotype
of tumor. These results obtained from in vivo were similar
to that obtained from in vitro.
In conclusion, our results from human SSCC samples,
A431 cell and nude mice model show that the main func-
tion of NET-1 gene as ‘‘molecular facilitators’’ may be
involved in cell proliferation and migration, carcinoma
differentiation and infiltration, tumor development and
progress process and may play a tumor-related gene role, or
as a candidate gene for diagnosis and a target gene for
therapy of skin carcinomas. Therefore, the functions of
NET-1 gene and its molecular pathogenesis in influencing
biological behavior of SSCC should be furthermore
investigated.
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